Loading
A phase 2 trial of Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder is a phase 2 interventional study registered as NCT07475806 by Astellas Pharma Global Development, Inc., with 240 participants planned, started 2026-03-12 and due to reach its primary completion in 2027-11-30. Interventions recorded: Enfortumab Vedotin and Pembrolizumab.
Shares Enfortumab vedotin, Astellas, Muscle-invasive and advanced bladder cancer, Pfizer (incl. Seagen) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Muscle-invasive and advanced bladder cancer, Pfizer (incl. Seagen) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.